214287-71-5

Basic information

• Product Name: 4-(cyclopropylethynyl)-5,6-difluoro-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one
• CAS NO: 214287-71-5
• Molecular Formula: C₁₄H₉F₅N₂O
• Molecular Weight: 316.2261
• Mol File: 214287-71-5.mol

Chemical Properties

• Boiling Point: 340.3°C at 760 mmHg
• Flash Point: 159.6°C
• Density: 1.54g/cm³
• Vapor Pressure: 8.67E-05mmHg at 25°C
• Refractive Index: 1.554
• CAS DataBase Reference: 4-(cyclopropylethynyl)-5,6-difluoro-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(cyclopropylethynyl)-5,6-difluoro-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one(214287-71-5)
• EPA Substance Registry System: 4-(cyclopropylethynyl)-5,6-difluoro-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one(214287-71-5)

Safety Data

• Hazardous Substances Data: 214287-71-5(Hazardous Substances Data)

Upstream product

• 201218-09-9 cyclopropyl acetylenyllithium 
• 214288-05-8 5,6-difluoro-4-trifluoromethylquinazolin-2(1H)-one 
• 214288-04-7 5,6-difluoro-3,4-dihydro-4-hydroxy-4-trifluoromethylquinazolin-2(1H)-one 
• 205756-47-4 o-aminotrifluoromethyl ketone 

Relevant articles and documents

Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors

A series of 4-alkenyl and 4-alkynyl-3,4-dihydro-4-(trifluoromethyl)-2- (1H)-quinazolinones were found to be potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) of human immunodeficiency virus type-1 (HIV-1). The 4-alkenyl-3,4-dihydro-4-(triflu

4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors

The present invention relates to 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones of formula I: or steroisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent, wherein: R1 is C1-3 alkyl substituted with 1-7 halogen; R2 is optionally substituted C1-5 alkyl, optionally substituted C2-5 alkenyl, or optionally substituted C2-5 alkynyl; R3, at each occurrence, is independently selected from C1-4 alkyl, OH, C1-4 alkoxy, F, Cl, Br, I, NR5R5a, NO2, CN, C(O)R6, NHC(O)R7, and NHC(O)NR5R5a; R5 and R5a are independently selected from H and C1-3 alkyl; R6 is selected from H, OH, C1-4 alkyl, C1-4 alkoxy, and NR5R5a; R7 is selected from C1-3 alkyl and C1-3 alkoxy; R8 is selected from H, C3-5 cycloalkyl, and C1-3 alkyl; and, n is selected from 0, 1, 2, 3, and 4.

4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinthiones useful as HIV reverse transcriptase inhibitors

The present invention relates to 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinthiones of formula I: or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.

Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1

A research program targeted toward the identification of expanded- spectrum nonnucleoside reverse transcriptase inhibitors which possess increased potency toward K103N-containing mutant human immunodeficiency virus (HIV) and which maintain pharmacokinetic